Puma Biotechnology

PBYI · NASDAQ

$10.76+$0.55 (+5.39%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $10.21

About PBYI

Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 179 full-time employees. The company went IPO on 2012-03-21. The firm is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The firm is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.

Employees: 179
Headquarters: Los Angeles, California
Listed: Mar 21, 2012
Sector: Health Care
Industry: Biotechnology
Website: pumabiotechnology.com

Leadership

Puma Biotechnology executives
Name	Title	Since	Age
Alan Auerbach	—	2010	55
Maximo Nougues	—	—	56
Douglas Hunt	—	—	60
Jay Moyes	—	—	71
Alessandra Cesano	—	—	64
Allison Dorval	—	—	49
Michael Miller	—	—	68
Adrian Senderowicz	—	—	61
Brian Stuglik	—	—	66
Troy Wilson	—	—	56
Mariann Ohanesian	—	2016	—

Revenue by product and region

Fiscal year ended Dec 31, 2021: $253.16M total revenue

By product

Product [Member]$189.06M74.7%
License [Member]$51.75M20.4%
Royalty [Member]$12.34M4.9%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Puma Biotechnology suppliers and customers
Company	Relationship	Country	Correlation
Celcuity CELC	Supplier and customer	US	0.93
Cardinal Health CAH	Customer	US	0.04
Knight Therapeutics GUD.TO	Supplier and customer	CA	-0.26
Cigna CI	Customer	US	-0.39
AmerisourceBergen ABC	Customer	US	-0.73
Centene CNC	Customer	US	-0.74
Pfizer PFE	Supplier and customer	US	-0.79
McKesson MCK	Customer	US	-0.81
UnitedHealth Group UNH	Customer	US	-0.84
CVS Health CVS	Customer	US	-0.85

Similar companies

Companies in the same industry as Puma Biotechnology

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.